Posted by Michael Wonder on 09 Sep 2016
Proposal relating to two HIV treatments (Tivicay and Kivexa)
9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and to amend the listing of a currently funded HIV treatment, abacavir sulphate with lamivudine (Kivexa).
This proposal has arisen as a result of a provisional agreement with GlaxoSmithKline NZ Limited.
In summary, this proposal would result in, from 1 November 2016:
- Dolutegravir (Tivicay) being funded via Special Authority criteria in the community and DHB hospitals for the treatment of HIV
- A decrease in the price and subsidy of abacavir sulphate with lamivudine (Kivexa)
- Delisting and subsidy protection being applied to each of Tivicay and Kivexa
Read PHARMAC Consultation